At CanSinoBIO, our main research and development focus is vaccines. To this end, we apply our expertise across a range targets from antigen discovery, antigen overexpression, purification and formulation to proof-of-concept pre-clinical evaluation, production process development and assay development.
Our team works with world’s most advanced equipment and lab resources for microbiology, molecular cell biology, immunology and biochemistry. We also maintain top- notch animal research facilities. Working alone and with partners, CanSinoBIO’s R&D team has nurtured a strong developmental pipeline over the years. We have an impressive array of vaccine candidates currently undergoing pre-clinical studies including recombinant protein-based pneumococcal vaccines, adenovirus-based recombinant TB vaccines, and polyvalent conjugate vaccines. Along with these , we have also developed novel carrier proteins and other viral vector-based new vaccine candidates. A number of vaccine-producing bacterial strains have also been engineered by us using recombinant technologies, and these strains allow us to accomplish exceptionally high vaccine yields while simplifying overall manufacturing processes. For example, our component pertussis vaccine has already advanced into the scaled-up production phase, and has been proven to outperform our peers in both quality and productivity. Additionally, it was our construction of a genetically detoxified diphtheria toxoid CRM197-overexpressing corynebacterium diphtheria strain that brought about a industry technical breakthrough in carrier protein production.